|
US20090298179A1
(en)
*
|
2003-04-29 |
2009-12-03 |
Connie Erickson-Miller |
Methods For Treating Degenerative Diseases/Injuries
|
|
EP2387998A1
(en)
*
|
2003-04-29 |
2011-11-23 |
Glaxosmithkline LLC |
Methods for treating degenerative diseases/injuries
|
|
US20090143453A1
(en)
*
|
2003-04-29 |
2009-06-04 |
Connie Erickson-Miller |
Methods for treating degenerative diseases/injuries
|
|
US20090048318A1
(en)
*
|
2003-04-29 |
2009-02-19 |
Connie Erickson-Miller |
Methods for treating degenerative diseases/injuries
|
|
US8354427B2
(en)
*
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
US7625890B2
(en)
*
|
2005-11-10 |
2009-12-01 |
Smithkline Beecham Corp. |
Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
|
|
HUE025173T2
(hu)
|
2005-12-13 |
2016-01-28 |
Incyte Corp |
Heteroaril-szubsztituált pirrollo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
|
|
PL1962830T3
(pl)
*
|
2005-12-23 |
2013-08-30 |
Glaxosmithkline Llc |
Azaindolowe inhibitory kinaz aurora
|
|
JP2009530342A
(ja)
*
|
2006-03-20 |
2009-08-27 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｂｔｋおよびｓｙｋ蛋白キナーゼを阻害する方法
|
|
CL2007003244A1
(es)
|
2006-11-16 |
2008-04-04 |
Millennium Pharm Inc |
Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
|
|
UY30892A1
(es)
*
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
|
SI2740731T1
(sl)
|
2007-06-13 |
2016-07-29 |
Incyte Holdings Coroporation |
Kristalinične soli inhibitorja za janus kinazo (r)-3-(4-(7h-pirolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopen tilpropannitrila
|
|
AR070127A1
(es)
*
|
2008-01-11 |
2010-03-17 |
Novartis Ag |
Pirrolo - pirimidinas y pirrolo -piridinas
|
|
EP2276346B1
(en)
|
2008-04-30 |
2016-11-23 |
National Health Research Institutes |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
|
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
ES2590904T3
(es)
*
|
2008-10-17 |
2016-11-24 |
Akaal Pharma Pty Ltd |
Moduladores de receptores de S1P y uso de los mismos
|
|
WO2010042998A1
(en)
|
2008-10-17 |
2010-04-22 |
Akaal Pharma Pty Ltd |
S1p receptors modulators
|
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
|
EP2198710A1
(de)
|
2008-12-19 |
2010-06-23 |
Bayer CropScience AG |
Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
|
|
MX2011006725A
(es)
*
|
2008-12-22 |
2011-09-15 |
Millennium Pharm Inc |
Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
|
|
US8609711B2
(en)
*
|
2009-01-30 |
2013-12-17 |
Glaxosmithkline Llc |
Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride
|
|
JO3635B1
(ar)
|
2009-05-18 |
2020-08-27 |
Millennium Pharm Inc |
مركبات صيدلانية صلبة وطرق لانتاجها
|
|
JP6172939B2
(ja)
|
2009-05-22 |
2017-08-02 |
インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｊａｋ阻害薬としての３−［４−（７ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１ｈ−ピラゾール−１−イル］オクタン−またはヘプタン−ニトリル
|
|
BRPI1012159B1
(pt)
*
|
2009-05-22 |
2022-01-25 |
Incyte Holdings Corporation |
Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
|
|
JO3434B1
(ar)
*
|
2009-07-31 |
2019-10-20 |
Millennium Pharm Inc |
مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
|
|
SG178092A1
(en)
|
2009-08-24 |
2012-03-29 |
Ascepion Pharmaceuticals Inc |
5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
|
|
US9249145B2
(en)
*
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
EP2308866A1
(de)
*
|
2009-10-09 |
2011-04-13 |
Bayer CropScience AG |
Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
|
|
MX337575B
(es)
|
2009-10-09 |
2016-03-10 |
Zafgen Corp |
Compuestos de sulfona y métodos para lafabricación y uso de éstos.
|
|
CA2788774A1
(en)
|
2010-02-19 |
2011-08-25 |
Millennium Pharmaceuticals, Inc. |
Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
|
|
CN102985417B
(zh)
|
2010-03-10 |
2015-01-28 |
因塞特公司 |
作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物
|
|
WO2011143669A2
(en)
|
2010-05-14 |
2011-11-17 |
Dana-Farber Cancer Institute, Inc |
Compositions and methods for treating neoplasia, inflammatory disease and other disorders
|
|
CN103154246B
(zh)
|
2010-05-14 |
2015-11-25 |
达那-法伯癌症研究所 |
用于治疗白血病的组合物和方法
|
|
WO2011143657A1
(en)
|
2010-05-14 |
2011-11-17 |
Dana-Farber Cancer Institute, Inc. |
Male contraceptive compositions and methods of use
|
|
MY161078A
(en)
|
2010-05-21 |
2017-04-14 |
Incyte Holdings Corp |
Topical formulation for a jak inhibitor
|
|
BR112013001613A2
(pt)
|
2010-07-22 |
2016-05-24 |
Zafgen Inc |
compostos tricíclicos e métodos para fazer e usar os mesmos.
|
|
EP2640725B1
(en)
|
2010-11-19 |
2015-01-07 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
|
US8933085B2
(en)
|
2010-11-19 |
2015-01-13 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
|
CA2825408A1
(en)
|
2011-01-26 |
2012-08-02 |
Zafgen, Inc. |
Tetrazole compounds and methods of making and using same
|
|
AU2012253759B2
(en)
|
2011-05-06 |
2016-01-21 |
Zafgen Inc. |
Tricyclic sulfonamide compounds and methods of making and using same
|
|
EA025526B1
(ru)
|
2011-05-06 |
2017-01-30 |
Зафджен Инк. |
Частично насыщенные трициклические соединения и способы их получения и применения
|
|
CN103764652B
(zh)
|
2011-05-06 |
2016-03-23 |
扎夫根股份有限公司 |
三环吡唑磺酰胺化合物及其制备和使用方法
|
|
EA201490042A1
(ru)
|
2011-06-20 |
2014-10-30 |
Инсайт Корпорейшн |
Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
US9359369B2
(en)
|
2012-01-18 |
2016-06-07 |
Zafgen, Inc. |
Tricyclic sulfonamide compounds and methods of making and using same
|
|
CA2861381A1
(en)
|
2012-01-18 |
2013-07-25 |
Zafgen, Inc. |
Tricyclic sulfone compounds and methods of making and using same
|
|
US20130303519A1
(en)
|
2012-03-20 |
2013-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treating cancer using aurora kinase inhibitors
|
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
|
AU2013282869B2
(en)
|
2012-06-29 |
2015-12-24 |
Pfizer Inc. |
Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
|
|
CN103664936A
(zh)
*
|
2012-09-17 |
2014-03-26 |
杨育新 |
一类治疗创伤性脑损伤疾病的化合物及其用途
|
|
CN103800345A
(zh)
*
|
2012-11-02 |
2014-05-21 |
常辉 |
一类治疗精神分裂症的化合物及其用途
|
|
JP2015536981A
(ja)
|
2012-11-05 |
2015-12-24 |
ザフゲン，インコーポレイテッド |
三環式化合物ならびにその製造および使用方法
|
|
CA2890343A1
(en)
|
2012-11-05 |
2014-05-08 |
Zafgen, Inc. |
Tricyclic compounds useful in the treatment of liver disorders
|
|
BR112015010223A2
(pt)
|
2012-11-05 |
2017-07-11 |
Zafgen Inc |
compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
|
|
TWI761825B
(zh)
|
2012-11-15 |
2022-04-21 |
美商英塞特控股公司 |
盧梭利替尼之緩釋性劑型
|
|
WO2014134391A1
(en)
|
2013-02-28 |
2014-09-04 |
Bristol-Myers Squibb Company |
Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
|
|
TW201444798A
(zh)
|
2013-02-28 |
2014-12-01 |
必治妥美雅史谷比公司 |
作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
|
|
EP2964650B1
(en)
|
2013-03-06 |
2018-12-05 |
Incyte Holdings Corporation |
Processes and intermediates for making a jak inhibitor
|
|
CN105324380A
(zh)
|
2013-03-14 |
2016-02-10 |
艾伯维公司 |
吡咯并[2,3-b]吡啶cdk9激酶抑制剂
|
|
TW201444836A
(zh)
*
|
2013-03-14 |
2014-12-01 |
Abbvie Inc |
吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
|
|
EP2976086B1
(en)
|
2013-03-22 |
2020-10-14 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
|
KR20160034379A
(ko)
|
2013-07-25 |
2016-03-29 |
다나-파버 캔서 인스티튜트 인크. |
전사 인자의 억제제 및 그의 용도
|
|
IL277554B2
(en)
|
2013-08-07 |
2024-03-01 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
|
JP6637884B2
(ja)
|
2013-11-08 |
2020-01-29 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
|
|
US9695171B2
(en)
|
2013-12-17 |
2017-07-04 |
Pfizer Inc. |
3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
|
|
US10793571B2
(en)
|
2014-01-31 |
2020-10-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
CN106029653A
(zh)
|
2014-01-31 |
2016-10-12 |
达纳-法伯癌症研究所股份有限公司 |
二氨基嘧啶苯砜衍生物及其用途
|
|
SG11201607108XA
(en)
|
2014-02-28 |
2016-09-29 |
Tensha Therapeutics Inc |
Treatment of conditions associated with hyperinsulinaemia
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
JP2017525759A
(ja)
|
2014-08-08 |
2017-09-07 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
ジヒドロプテリジノン誘導体およびその使用
|
|
CA2955074A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
|
AU2015339511B2
(en)
|
2014-10-27 |
2020-05-14 |
Tensha Therapeutics, Inc. |
Bromodomain inhibitors
|
|
PE20171789A1
(es)
*
|
2015-03-02 |
2017-12-28 |
Bristol Myers Squibb Co |
Inhibidores del factor beta de crecimiento de transformacion (tgf-beta)
|
|
US10702527B2
(en)
|
2015-06-12 |
2020-07-07 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
EP3324976A4
(en)
|
2015-07-21 |
2019-03-27 |
Millennium Pharmaceuticals, Inc. |
ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
|
|
RU2018112953A
(ru)
|
2015-09-11 |
2019-10-14 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Ацетамидтиенотриазолодиазепины и пути их применения
|
|
CR20180200A
(es)
|
2015-09-11 |
2018-05-31 |
Dana Farber Cancer Inst Inc |
Ciano tienotriazolpirazinas y usos de las mismas
|
|
AU2016322813B2
(en)
|
2015-09-14 |
2021-04-01 |
Pfizer Inc. |
Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
|
|
WO2017091673A2
(en)
|
2015-11-25 |
2017-06-01 |
Dana-Farber Cancer Institute, Inc. |
Bivalent bromodomain inhibtors and uses thereof
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
SMT202200195T1
(it)
|
2018-01-30 |
2022-07-21 |
Incyte Corp |
Procedimenti per preparare (1-(3-fluoro-2-(trifluorometil)isonicotinil)piperidin-4-one)
|
|
EP3773593B1
(en)
|
2018-03-30 |
2024-05-15 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using jak inhibitors
|
|
WO2020223456A1
(en)
*
|
2019-05-01 |
2020-11-05 |
Nemucore Medical Innovations, Inc. |
Degradation of aurora kinase (aurk) by conjugation of aurk inhibitors with e3 ligase ligand
|
|
US20220267321A1
(en)
*
|
2019-06-27 |
2022-08-25 |
Medshine Discovery Inc. |
Azaindole pyrazole compounds as cdk9 inhibitors
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
CN112225723B
(zh)
*
|
2020-12-16 |
2021-03-30 |
北京华氏开元医药科技有限公司 |
一种吲哚类衍生物、制备方法及应用
|
|
WO2022135580A1
(zh)
*
|
2020-12-25 |
2022-06-30 |
南京明德新药研发有限公司 |
吡啶并吡咯类化合物的晶型、制备方法及其应用
|
|
CN115572294B
(zh)
*
|
2022-11-13 |
2023-11-21 |
药康众拓(江苏)医药科技有限公司 |
一种氘代氮杂吲哚联吡唑类化合物、药物组合物和用途
|